ReviewInternational journal of molecular sciences2019
Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- Clinical impact of MRI-based risk calculators for prostate cancer diagnosis: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2026Pooled it
- Evaluation of a Methylated Circulating Tumour DNA Panel for Detection and Disease Stratification in Prostate Cancer.International journal of molecular sciences · 2026Article
- Combined radiomics, PI-RADS, and clinical model improve significant prostate cancer prediction and guide biopsy decision.Insights into imaging · 2026Article
- Comparison of prostate cancer diagnostic models based on PCA3 and TMPRSS2:ERG RNA biomarkers from post-DRE and non-DRE urine specimens.World journal of urology · 2026Article
- Coping with Complications that Occur after Prostate Biopsy for Satisfactory Evaluation of Call Service Using Artificial Intelligence: A Pilot Randomized Controlled Trial.The world journal of men's health · 2025Article
- Article
- Transforming Prostate Cancer Care: Innovations in Diagnosis, Treatment, and Future Directions.International journal of molecular sciences · 2025Review
- Stratified/risk-based screening for colorectal cancer in the UK: an overview.Colorectal cancer · 2025Review
- Cancer detection in patients with prostate-specific antigen levels within the grey zone: can synthetic magnetic resonance imaging aid in the differentiation between prostate cancer and noncancerous lesions?Quantitative imaging in medicine and surgery · 2024Article
- From molecular mechanisms of prostate cancer to translational applications: based on multi-omics fusion analysis and intelligent medicine.Health information science and systems · 2024Review
- Article
- Review
- Review
- Investigating Efficient Risk-Stratified Pathways for the Early Detection of Clinically Significant Prostate Cancer.Journal of personalized medicine · 2024Article
- Navigating through the Controversies and Emerging Paradigms in Early Detection of Prostate Cancer: Bridging the Gap from Classic RCTs to Modern Population-Based Pilot Programs.Journal of personalized medicine · 2023Article
- Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer.Diagnostics (Basel, Switzerland) · 2023Review
- Use of artificial intelligence in discerning the need for prostate biopsy and readiness for clinical practice: a systematic review protocol.Systematic reviews · 2023Article
- Relationship between Proclarix and the Aggressiveness of Prostate Cancer.Molecular diagnosis & therapy · 2023Article
- Re-evaluating the diagnostic efficacy of PSA as a referral test to detect clinically significant prostate cancer in contemporary MRI-based image-guided biopsy pathways.Journal of clinical urology · 2023Article
- Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer.European urology open science · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review discusses the most recent evidence for currently available risk stratification tools in the detection of clinically significant prostate cancer (csPCa), and evaluates diagnostic strategies that combine these tools. Novel blood biomarkers, such as the Prostate Health Index (PHI) and 4Kscore, show similar ability to predict csPCa. Prostate cancer antigen 3 (PCA3) is a urinary biomarker that has inferior prediction of csPCa compared to PHI, but may be combined with other markers like TMPRSS2-ERG to improve its performance. Original risk calculators (RCs) have the advantage of incorporating easy to retrieve clinical variables and being freely accessible as a web tool/mobile application. RCs perform similarly well as most novel biomarkers. New promising risk models including novel (genetic) markers are the SelectMDx and Stockholm-3 model (S3M). Prostate magnetic resonance imaging (MRI) has evolved as an appealing tool in the diagnostic arsenal with even stratifying abilities, including in the initial biopsy setting. Merging biomarkers, RCs and MRI results in higher performances than their use as standalone tests. In the current era of prostate MRI, the way forward seems to be multivariable risk assessment based on blood and clinical parameters, potentially extended with information from urine samples, as a triaging test for the selection of candidates for MRI and biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.